Prestige Biologics Co (334970) Fair Value & Analysis
Healthcare · KR · Market cap 148B KRW
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 11 days ago
Fair value updated Jun 24, 2026 — revised from 7,649 KRW to 7,706 KRW (+0.8%) since Jun 23, 2026. Share price +7.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,631 KRW – 4,568 KRW · fair‑value band 5,780 KRW – 9,633 KRW · the 1,878 KRW price screens below the 7,706 KRW fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Prestige Biologics Co (334970) currently trades at 1,878 KRW, while our model-based Fair Value estimate is 7,706 KRW — implying the stock looks roughly 310.3% undervalued today. We read business quality at 23/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at 2.8B KRW. Net debt stands at 89.9B KRW. Fundamentals as of Jun 24, 2026
Our scenario range runs from 5,780 KRW (bear case) to 9,633 KRW (bull case); at 1,878 KRW, the current price sits below that range. The share trades about 64% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at 310%, 334970 screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known as PrestigeBio Pharmaceuticals and changed its name to Prestige Biologics Co., Ltd. in October 2019. The company was founded in 2015 and is based in Cheongju-si, South Korea.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Prestige Biologics Co reported revenue of 12.5B KRW in FY2024 versus 0 KRW in FY2020. Reported net income was −27.5B KRW in FY2024.
Is 334970 fairly valued? → Check now
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ST Pharm Co 237690 | 117,800 KRW | 62,226 KRW | -47% |
| NatureCell Co 007390 | 25,100 KRW | 6,531 KRW | -74% |
| Oscotec Inc 039200 | 41,750 KRW | 29,033 KRW | -30% |
| DongKook Pharmaceutical Co 086450 | 17,280 KRW | 25,989 KRW | +50% |
| Kolon Life Science Inc 102940 | 49,200 KRW | 48,134 KRW | -2% |
| Huons Global Co 084110 | 27,350 KRW | 47,691 KRW | +74% |
| BINEX Co 053030 | 7,940 KRW | 4,024 KRW | -49% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 22,700 KRW | 49,475 KRW | +118% |
| Vivozon Pharmaceutical Co 082800 | 4,045 KRW | 1,992 KRW | -51% |
| EURO EURO | 1.07 PHP | 0.7800 PHP | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Prestige Biologics Co (334970) undervalued?
What is the fair value of 334970?
What is the quality score of 334970?
What is the revenue of Prestige Biologics Co (334970)?
What is the net profit margin of 334970?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.